Most likely
B+
Bull case
45%
Probability
Target price
$16.25
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
PSNL
PersonalisDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q2 print supports a strengthening commercial trajectory: clinical volume, clinical revenue, Medicare coverage, and physician adoption all improved materially. The Tempus transaction also provides a potential near-term value reference at $16.25 per share.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -1.1.
What can break
Clinical growth depends on reimbursement expansion, physician adoption, and continued evidence generation.
Momentum
92
Value
41
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.25 · Bull $16.25 · Bear $11.50Analysis 2026-08-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $16.25
Why
Momentum92 · Δ7d -5.1
Value41 · Δ7d -0.1
Sentiment51 · Δ7d -1.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -1.1.
Contradictions & invalidation
- • Clinical growth depends on reimbursement expansion, physician adoption, and continued evidence generation.
- • Insider Form 4 activity included open-market sales by senior officers; this is a sentiment and alignment risk, not evidence of operating deterioration. [#SEC-FORM4-2026-07-15] [#SEC-FORM4-2026-07-09]
- • The deal creates a closing and consideration risk, while Personalis remains loss-making and has limited analyst coverage.
Catalyst clock
2026-08-04
Q2 clinical and reimbursement acceleration
Lead driver: Sentiment · See AI snapshot
Momentum
92
8% active weight
Current posture
7d trendSoftening
Δ7d
-5.1
Δ21d
-4.0
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
51
45% active weight
Current posture
7d trendSoftening
Δ7d
-1.1
Δ21d
-3.3
Why this grade
Composite grade D. Momentum 92.2 / Value 40.6 / Sentiment 50.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-14. Scenario method
B
Base case
40%
Probability
Target price
$15.25
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
15%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.69B
Beta
1.99
Shares Out
106.8M
P/E (TTM) · Derived
-17.4
P/S (TTM)
10.31
P/FCF (TTM) · Derived
-15.35
Rev YoY
+30.0%
EPS YoY
+32.6%
Gross Margin
+12.7%
Op Margin
-164.1%
Net Debt
-$199.14M
Current Ratio
5.24
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data